File Download
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1016/j.ebcr.2017.07.002
- Scopus: eid_2-s2.0-85029501403
- WOS: WOS:000416287600017
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: Effect of plasmapheresis on serum levels of clobazam, levetiracetam and topiramate
| Title | Effect of plasmapheresis on serum levels of clobazam, levetiracetam and topiramate |
|---|---|
| Authors | |
| Issue Date | 2017 |
| Publisher | Elsevier: Creative Commons. The Journal's web site is located at http://www.journals.elsevier.com/epilepsy-and-behavior-case-reports/ |
| Citation | Epilepsy & Behavior Case Reports, 2017, v. 8, p. 66-68 How to Cite? |
| Abstract | A 27-year-old man with a diagnosis of new onset refractory status epilepticus (NORSE) was treated with five antiseizure drugs (ASDs) including clobazam, levetiracetamand topiramate. He received plasma exchange (PE) for presumed autoimmune etiology. SerumASD levels were seriallymonitored in two sessions. Levels of clobazam, levetiracetam and topiramate were significant reduced by PE. Serum clobazam level dropped down to at least 85% and 75% of the baseline during and after the procedure respectively; levetiracetam dropped down to 83% and 83%; and topiramate dropped to 86% and 79%. The results may imply a theoretical risk of breakthrough seizure during PE due to low ASD levels. |
| Persistent Identifier | http://hdl.handle.net/10722/259431 |
| ISSN | |
| ISI Accession Number ID |
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | To, HHM | - |
| dc.contributor.author | Chang, RSK | - |
| dc.contributor.author | Chan, AOK | - |
| dc.contributor.author | Chan, WLP | - |
| dc.date.accessioned | 2018-09-03T04:07:18Z | - |
| dc.date.available | 2018-09-03T04:07:18Z | - |
| dc.date.issued | 2017 | - |
| dc.identifier.citation | Epilepsy & Behavior Case Reports, 2017, v. 8, p. 66-68 | - |
| dc.identifier.issn | 2213-3232 | - |
| dc.identifier.uri | http://hdl.handle.net/10722/259431 | - |
| dc.description.abstract | A 27-year-old man with a diagnosis of new onset refractory status epilepticus (NORSE) was treated with five antiseizure drugs (ASDs) including clobazam, levetiracetamand topiramate. He received plasma exchange (PE) for presumed autoimmune etiology. SerumASD levels were seriallymonitored in two sessions. Levels of clobazam, levetiracetam and topiramate were significant reduced by PE. Serum clobazam level dropped down to at least 85% and 75% of the baseline during and after the procedure respectively; levetiracetam dropped down to 83% and 83%; and topiramate dropped to 86% and 79%. The results may imply a theoretical risk of breakthrough seizure during PE due to low ASD levels. | - |
| dc.language | eng | - |
| dc.publisher | Elsevier: Creative Commons. The Journal's web site is located at http://www.journals.elsevier.com/epilepsy-and-behavior-case-reports/ | - |
| dc.relation.ispartof | Epilepsy & Behavior Case Reports | - |
| dc.rights | This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. | - |
| dc.title | Effect of plasmapheresis on serum levels of clobazam, levetiracetam and topiramate | - |
| dc.type | Article | - |
| dc.identifier.email | Chan, WLP: pwlchan@hku.hk | - |
| dc.description.nature | published_or_final_version | - |
| dc.identifier.doi | 10.1016/j.ebcr.2017.07.002 | - |
| dc.identifier.scopus | eid_2-s2.0-85029501403 | - |
| dc.identifier.hkuros | 288397 | - |
| dc.identifier.volume | 8 | - |
| dc.identifier.spage | 66 | - |
| dc.identifier.epage | 68 | - |
| dc.identifier.isi | WOS:000416287600017 | - |
| dc.publisher.place | Netherlands | - |
| dc.identifier.issnl | 2213-3232 | - |